Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 21, 2020, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 21, 2020, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.".